PROGRESS IN ALZHEIMER’S DISEASE RESEARCH
ERT’s Vice President of Trial Oversight, Chief Diversity Officer, and Trial Better podcast host, Otis Johnson, sits down with Dr. Eric Siemers, President of Siemers Integration, LLC and a Distinguished Medical Advisor at Cogstate. They discuss the past and current state of Alzheimer’s disease research, and take an optimistic look ahead at potential advancements in the field.
Access Trial Better Podcast from your favorite channels:
Dr. Eric Siemers, President, Siemers Integration, LLC; Distinguished Medical Advisor, Cogstate
Dr. Siemers’ experience in clinical trials of neurodegenerative disease spans over 25 years, with a focus on the development of trial designs that fully characterize the effects of investigational drugs – including effects in individuals before the onset of clinical symptoms. Dr. Siemers served as Distinguished Medical Fellow for Lilly’s Alzheimer’s Disease Global Development Team, where he was responsible for the design and implementation of 5 large phase III clinical studies of AD, in addition to playing a major collaborative role in 2 public-private partnership studies. Dr. Siemers served as a member of the NIA/Alzheimer’s Association working group that developed the “Research Framework” that defines the entire Alzheimer’s disease continuum. He also served on the Board of Directors of the American Society of Experimental Neurotherapeutics, was a founding member and past Chair of the Alzheimer’s Association Research Roundtable, and is a Steering Committee member for the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Dr. Siemers earned his MD with highest distinction from the Indiana University School of Medicine, where he completed an internship in the Department of Internal Medicine and residency in the Department of Neurology.